KCT0007415已完成未知
An Assessment of Safety and Efficacy of the abdominal subcutaneous fat reduction effects of ALPHA: Prospective, Multicenter, Single arm and Academic clinical trial
Chung-Ang Univerisity Hospital0 个研究点目标入组 25 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 65(Year)（—）
- 性别
- All
入选标准
- •1) Men and women aged 19 to 65 years (international age)
- •2) Subjects whose abdominal fat is clearly visible and the abdominal fat thickness under the umbilicus measured by caliper ? 1.5 cm [19]
- •3) Subjects with BMI ? 35 kg/m2 [31][32]
- •4) Subjects with weight change ? 5% from the past month [20][21]
- •5) Subjects who agreed to maintain their weight (ie, weight change ? 5%) by not changing their daily personal habits such as eating habits, exercise habits and lifestyle during the entire clinical trial [20][21]
- •6) Subjects who can understand and follow instructions and be able to participate throughout the clinical trial.
- •7) Subjects who voluntarily decided to participate in this clinical trial and gave written consent to the subject consent form.
排除标准
- •1) Subjects with sagging skin with no elasticity in the abdomen.
- •2) In the past 6 months, subjects who received the abdominal liposuction, abdominoplasty, mesotherapy, HIFU, cryolipolysis, dermal filler, radiofrequency or laser treatment, or chemical dermabrasion, Botulinum toxin injection, etc., which are considered to have an impact on this clinical trial; subjects who received non-surgical treatment.
- •3) Subjects with scars from open treatment (laparoscopic treatment) on the abdomen
- •4) Subjects with the abdominal dermatological abnormalities (injury marks, keloid skin, abnormal wound healing, open wounds), hernias or acute and chronic dermatological lesions (dermatitis, vitiligo, eczema, rash, psoriasis), systemic lupus erythematosus, scleroderma, etc.), skin paresthesia, peripheral circulatory insufficiency
- •5) Subjects sensitive to cold and heat, such as Raynaud's phenomenon, cold urticaria, cryoglobulinemia, and paroxysmal cold hemoglobinuria
- •6) Subjects taking drugs that affect weight loss or undergoing therapy (including exercise therapy)
- •7) Subjects with implanted devices containing metals or cardiac pacemakers, defibrillators, drug delivery systems
- •8) Subjects who have participated in other clinical trials within 6 months from the screening date or are currently participating in other clinical trials
- •9) Subjects who have a blood clotting disorder-related disease in the body, such as hemostasis or thrombosis, or receive anticoagulant therapy, anticoagulant drugs, or anticoagulant diet to treat these diseases
- •10) Subjects who have been diagnosed with or are currently receiving treatment for Lipid metabolism disease, autoimmune disease not controlled by drugs, severe cardiovascular disease, severe diabetes, severe liver disease or severe kidney disease, mental disease, neurological disorder that may have a significant effect on this clinical trial
- •11) Pregnant or lactating women
- •12) Subjects who do not agree to contraception* by a medically accepted method until 12 weeks (17 weeks of clinical trial period) after the last treatment of the clinical trial medical device in this clinical trial among female subjects of childbearing potential * Medically accepted contraceptive methods: condoms, oral contraceptives lasting for at least 4 months, use of injectable or implantable contraceptives, installation of intrauterine contraceptives, etc.
- •13) Subjects who are judged inappropriate to participate in clinical trials by the judgment of investigators
研究者
相似试验
招募中
不适用
Effect of Abdominal Massage on the Gastric Residual Volume (GRV) among Patients with Nasogastric (NG) Tube Feeding Admitted in Intensive Care Units (ICU).CTRI/2022/01/039689ot funded by any institution its self funded
已完成
不适用
The Efficacy and Safety of Using Prophylactic Abdominal Drainage After CholecystectomyDrainageLaparoscopic CholecystectomyAcute CholecystitisNCT05267860University of Aleppo232
进行中（未招募）
1 期
se of an antidiabetic drug (Empagliflozin) to lower the blood level of 1,5-anhydroglucitol in patients deficient in the glucose-6-phosphate transporter (GSD1b) and the phosphatase G6PC3, both of the endoplasmic reticulum, to treat their recurrent infections by normalizing their blood neutrophil counts. Neutrophils are the most abundant white blood cells in our blood that are essential to help fighting infections. 1,5-anhydroglucitol is a sugar derivative with no known function.(1) Severe Congenital Neutropenia type 4 (SNC4) due to a deficiency in G6PC3, a phosphatase of the endoplasmic also known a Ubiquitous glucose-6-phosphatase and (2) the neutropenia in Glycogen Storage Disease type 1b due to a deficiency in the glucose-6-phosphate transporter (G6PT / SLC37A4) of the endoplasmic reticulum.EUCTR2018-004191-35-BECliniques universitaires Saint-Luc5
尚未招募
1 期
Observation of the Therapeutic Efficacy of Abdominal Massage Therapy for Generalized Anxiety Disorder and Its Effects on Intestinal MicrobiotaGeneralized Anxiety DisorderITMCTR2024000140First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
进行中（未招募）
1 期
Efficacy and Safety assessments of a peritoneal dialysis solution containing Glucose, Xylitol and L-Carnitine compared to standard PD solutions in Continuous Ambulatory Peritoneal Dialysis (CAPD) - NDEUCTR2009-016801-40-ITIPERBOREAL PHARMA13